Social protection to reduce financial burden of tuberculosis in Timor-Leste (TB-PROTECT): a cluster randomized trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
To evaluate whether a tuberculosis (TB)-specific cash transfer reduces the proportion of households facing catastrophic costs and to assess its effects on treatment success and financial burden in Timor-Leste. We conducted a non-blinded, cluster-randomized controlled trial across 32 community health centers, December 2022-September 2023. Health centers were randomized 1:1 to intervention or control (16 clusters per arm), and outcomes were assessed at the individual and household level. Patients aged ≥ 17 years initiating standard treatment were enrolled. Intervention clusters provided an unconditional, TB-specific cash transfer (US$ 30 monthly for six months); control clusters provided standard care. The primary outcome was the proportion of households incurring catastrophic costs (> 20% of annual household income); in the intervention clusters, the cash transfer received was subtracted from indirect costs in this calculation. Costs were measured using a modified WHO TB Patient Cost Survey administered at two time points to reduce recall bias: pre-diagnosis costs within one week of enrollment and post-diagnosis costs at the end of the six-month treatment. Indirect costs were estimated using both the output approach and the human capital approach, with the output approach as the primary estimate. Analyses followed intention-to-treat principles using multivariate regression accounting for clustering. Among 329 patients enrolled across 32 clusters (161 intervention, 168 control; 16 clusters per arm), the proportion facing catastrophic costs was significantly lower in the intervention group (67.1%) than in the control group (94.6%; p < 0.001; adjusted relative risk 0.76, 95% CI 0.69–0.85). Mean net indirect costs were lower in the intervention group than in the control group (coefficient US$ − 230.68, 95% CI -328.99 to − 132.37). No significant differences were observed in non-medical costs or treatment success. No intervention-related adverse events were reported. Unconditional cash transfers significantly reduced catastrophic costs and indirect financial burden among tuberculosis patients but had no effect on treatment success. To achieve the goal of zero catastrophic costs, multidimensional social protection strategies addressing non-medical costs—including food and transport support—are essential alongside financial assistance. Clinical Research Information Service of Republic Korea: KCT0009506 (Retrospectively registered June 5th, 2024).
Fields of Study & Subjects
Healthcare Systems and Reforms
Tuberculosis Research and Epidemiology
Poverty
Education
and Child Welfare
Publication details
- Journal / source
- BMC Infectious Diseases
- Publication date
- 4 November 2026
- Language
- EN